899429-13-1

Basic information

• Product Name: tert-butyl [(1S,2S)-1-[(3,3-difluoropyrrolidin-1-yl)carbonyl]-3-(dimethylamino)-3-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridine-6-phenyl)propyl]carbamate
• Synonyms: tert-butyl [(1S,2S)-1-[(3,3-difluoropyrrolidin-1-yl)carbonyl]-3-(dimethylamino)-3-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridine-6-phenyl)propyl]carbamate
• CAS NO: 899429-13-1
• Molecular Weight: 542.586
• Mol File: 899429-13-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tert-butyl [(1S,2S)-1-[(3,3-difluoropyrrolidin-1-yl)carbonyl]-3-(dimethylamino)-3-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridine-6-phenyl)propyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl [(1S,2S)-1-[(3,3-difluoropyrrolidin-1-yl)carbonyl]-3-(dimethylamino)-3-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridine-6-phenyl)propyl]carbamate(899429-13-1)
• EPA Substance Registry System: tert-butyl [(1S,2S)-1-[(3,3-difluoropyrrolidin-1-yl)carbonyl]-3-(dimethylamino)-3-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridine-6-phenyl)propyl]carbamate(899429-13-1)

Safety Data

• Hazardous Substances Data: 899429-13-1(Hazardous Substances Data)

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 690258-05-0 (2S,3S)-N-(tert-butoxycarbonyl)amino-2-(4-bromophenyl)-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxobutanamide 
• 899429-12-0 (2S,3S)-2-(4-Bromo-phenyl)-3-tert-butoxycarbonylamino-4-(3,3-difluoro-pyrrolidin-1-yl)-4-oxo-butyric acid 
• 356560-80-0 6-bromo[1,2,4]triazolo[1,5-a]pyridine 
• 690258-06-1 (2S,3S)-3-N-(tert-butoxycarbonyl)amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]butanamide 

Relevant articles and documents

(2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1, 2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: A selective α-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

A series of β-substituted biarylphenylalanine amides were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the metabolic profile of early analogues led to the discovery of (2S